Current price
$45.25
Loading...
Public stock page preview
Travere Therapeutics
TVTX
Why is Travere Therapeutics stock moving today?
See what stands out in TVTX today: the price move, unusual volume, recent trend, and what to watch next. Unlock the full analysis for the deeper driver breakdown.
Today vs prev close
+5.33%
Volume vs average
0.2x
Market cap
$4.2B
Why is TVTX stock up or down today?
Travere Therapeutics (TVTX) is up 5.33% today at $45.25. Trading volume is running at about 0.2x its 3-month average, which suggests the move is drawing more attention than a routine session. The stock is trading near its 52-week high. Travere Therapeutics sits in Biotechnology within Healthcare.
Over the last five trading sessions, the stock is down 5.26%. Across the last month of trading data on this page, shares are up 0.76%. The next reported earnings date is May 4, 2026. The current mean analyst target on this page is $54.14.
AI summary and ranked drivers
See the full explanation layer built from the full signal set.
Unlock the full analysis to see the ranked drivers behind today's move, signal-by-signal context, and deeper watchlist monitoring.
Is TVTX moving on unusual volume or trend strength?
Volume is near normal at roughly 0.2x the 3-month average. The stock is currently trading near its 52-week high. Five-session trend: -5.26%. Today's trading range spans $43.09 to $45.46.
See volume and trend context
What should investors watch next in TVTX stock?
Next reported earnings date: May 4, 2026. Previous close was $42.96, which is the cleanest baseline for judging whether today's move is extending or reversing momentum. Mean analyst target is $54.14; large gaps between current price and the target can keep sentiment-sensitive names volatile. One-month return sits at +0.76%, which gives context on whether today's move is part of a larger trend.
See what to watch next
Price action timeline
Use the chart to frame today's move inside the broader trend.
Price timeline
TVTX Performance
Full analysis is locked
This public page shows the frame: live market data, trend context, and the next catalyst to watch. The premium layer is where the ranked driver breakdown, filing signals, and watchlist tracking live.
Catalyst ranking and confidence
Analyst revisions and target moves
Filing and insider signal layer
Watchlist-based daily monitoring
Learn the mechanics behind moves like this
Common questions about TVTX stock today
Why is TVTX stock moving today?
Travere Therapeutics (TVTX) is up 5.33% today at $45.25. Trading volume is running at about 0.2x its 3-month average, which suggests the move is drawing more attention than a routine session. The stock is trading near its 52-week high. Travere Therapeutics sits in Biotechnology within Healthcare. Over the last five trading sessions, the stock is down 5.26%. Across the last month of trading data on this page, shares are up 0.76%. The next reported earnings date is May 4, 2026. The current mean analyst target on this page is $54.14.
What happened to Travere Therapeutics stock today?
Travere Therapeutics stock is up 5.33% today, with the public page focusing on price action, trend, volume, and the next catalyst to watch.
Is TVTX moving on high volume today?
Volume is near normal at roughly 0.2x the 3-month average.
Is this move specific to TVTX or part of a bigger sector move?
Travere Therapeutics is currently being framed alongside the broader Healthcare group on this page, which helps separate stock-specific moves from broader sector pressure.
What should investors watch next for TVTX?
Next reported earnings date: May 4, 2026. Previous close was $42.96, which is the cleanest baseline for judging whether today's move is extending or reversing momentum. Mean analyst target is $54.14; large gaps between current price and the target can keep sentiment-sensitive names volatile. One-month return sits at +0.76%, which gives context on whether today's move is part of a larger trend.
When is TVTX earnings?
The next reported earnings date shown on this page is May 4, 2026.
WhyStockMove provides informational context and is not investment advice.